FMP
NASDAQ
1.59 USD
-0.03 (-1.89%)
Dr. David J. Woodhouse Ph.D.
Healthcare
Biotechnology
https://www.ngmbio.com
NASDAQ
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is...
0001426332
US62921N1054
62921N105
333 Oyster Point Boulevard
650 243 5555
US
138
Apr 4, 2019
0001426332
NASDAQ
Biotechnology
Healthcare
62921N105
US62921N1054
US
1.59
1.26
1.48M
132.71M
-
0.6-4.69
0.61
-
-
-
-
-0.92
-
https://www.ngmbio.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.